Can cannabis help reduce pain disparities in cancer patients?
NCT ID NCT06037681
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 600 black and white adults with solid tumor cancer who use cannabis at least weekly or not at all. Participants report pain, symptoms, and cannabis use through a smartphone app and surveys for one year. The goal is to understand how cannabis affects pain and opioid use, and whether it helps reduce racial differences in pain severity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Black and White patients from Local cancer centers of the Buffalo, Univsity of Pennsylvania and Thomas Jefferson Univeristy areas.
- Ages
-
21 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 21 years or older * Black or white race * Solid tumor cancer within 3 years of enrollment * Cannabis use of at least once a week or non cannabis use for 3 months * experience pain but spend less than 50% in bed or chair * Prescribed or take opioid for at least 30 days for pain * Not pregnant or planning to become pregnant in the next 12 months * English speaking Exclusion Criteria: * Lymphoma, leukemia, and melanoma * CBD only use * Synthetic cannabis use in past 3 months = Prescribed Medically-prescribed synthetic cannabis (e.g., dronabinol \[Marinol, Syndros\], Epidiolex) * race other than Black or White
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19144, United States
-
University at Buffalo
RECRUITINGBuffalo, New York, 14214, United States
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19176, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success
- Could a frailty score predict which older cancer patients survive intensive care?